神経刺激装置の世界市場：洞察、競合情勢、市場予測：2030年

世界の神経刺激装置の市場規模は、2023年に58億2,000万米ドルとなりました。同市場は、2024年から2030年までの予測期間中に11.77％のCAGRで拡大し、2030年には113億4,000万米ドルに達すると予測されています。神経刺激装置の需要は、主に片頭痛やてんかんなどの慢性神経疾患の発生率の増加、アドオン療法としての製品需要の高まり、うつ病や慢性疼痛などの生活習慣病の流行、技術的に進んだ製品の採用、予測期間中の高齢者人口の増加などが背景にあります。

脳卒中、脳およびその他の神経系がん、外傷性脳損傷、脊髄損傷、アルツハイマー病およびその他の認知症、パーキンソン病、てんかん、片頭痛などで構成される神経疾患は、障害の主な原因となっています。これらの疾患は、患者、その家族、社会にとって大きな負担を伴う最も蔓延している疾患の1つとして、ますます認識されるようになっています。てんかんセンターが2020年に発表したデータによると、世界中で約5,000万人の患者がてんかんと共存しており、毎年約240万人が新たに診断されています。さらに、てんかん患者の大半は特発性であり、原因が特定できていません。

パーキンソン病（PD）は、Global Burden of Disease Study 2019によると、常に人口1,000人当たり1～2人が罹患しています。PDの有病率は年齢とともに増加し、60歳以上の人口の1％がPDに罹患しています。

世界保健機関（WHO）のデータ（2023年）によると、世界で約5000万人が認知症であり、毎年1000万人近くが新たに発症しています。これらの症例の約60～70％はアルツハイマー型認知症です。したがって、この負担を軽減するための緊急対策が必要です。世界中で神経学的症例が増加していることから、神経刺激装置の市場需要が高まると予想されます。

企業はより優れた有効性と手軽さを備えた製品を開発するために研究開発を強化しています。神経疾患の治療において実証された製品の高い有効性は、疾患に対する限られた治療オプションの利用可能性とともに、予測期間中の市場成長を促進すると予想されます。また、神経刺激装置は電気的な脳信号を活性化または抑制することで簡単に治療ができるため、うつ病患者の増加も市場開発に貢献すると考えられます。

当レポートでは、世界の神経刺激装置市場について調査し、市場の概要とともに、装置タイプ別、用途別、タイプ別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 神経刺激装置市場レポートのイントロダクション

第2章 神経刺激装置市場のエグゼクティブサマリー

第3章 規制分析

• 米国
• 欧州
• 日本
• 中国

第4章 神経刺激装置市場の主な要因分析

• 神経刺激装置市場の促進要因
• 神経刺激装置市場の抑制要因と課題
• 神経刺激装置市場の機会

第5章 神経刺激装置におけるポーターのファイブフォース分析

第6章 神経刺激装置市場の概要

• 装置タイプ別
• 用途別
• タイプ別
• エンドユーザー別
• 地域別

第7章 神経刺激装置の企業と製品プロファイル

• Medtronic Plc
• Cyberonics
• Boston Scientific Corporation
• Abbott Laboratories
• Aleva neurotherapeutics SA
• ElectroCore Inc.
• EndoStim Inc.
• Nevro Corporation
• LivaNova PLC
• NDI Medical, LLC
• Neuronetics
• NeuroSigma Inc.
• CODMAN & SHURTLEFF'S
• INTRAPACE
• B. Braun SE Melsungen

第8章 KOL の見解

第9章 プロジェクトのアプローチ

第10章 DelveInsightのサービス内容

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: Neurostimulation Devices Market in Global (2021-2030)
• Table 3: Neurostimulation Devices Market in Global by Device Type (2021-2030)
• Table 4: Neurostimulation Devices Market in Global by Application (2021-2030)
• Table 5: Neurostimulation Devices Market in Global by Type (2021-2030)
• Table 6: Neurostimulation Devices Market in Global by Geography (2021-2030)
• Table 7: Neurostimulation Devices Market in North America (2021-2030)
• Table 8: Neurostimulation Devices Market in the US (2021-2030)
• Table 9: Neurostimulation Devices Market in Canada (2021-2030)
• Table 10: Neurostimulation Devices Market in Mexico (2021-2030)
• Table 11: Neurostimulation Devices Market in Europe (2021-2030)
• Table 12: Neurostimulation Devices Market in France (2021-2030)
• Table 13: Neurostimulation Devices Market in Germany (2021-2030)
• Table 14: Neurostimulation Devices Market in the United Kingdom (2021-2030)
• Table 15: Neurostimulation Devices Market in Italy (2021-2030)
• Table 16: Neurostimulation Devices Market in Spain (2021-2030)
• Table 17: Neurostimulation Devices Market in Rest of Europe (2021-2030)
• Table 18: Neurostimulation Devices Market in Asia-Pacific (2021-2030)
• Table 19: Neurostimulation Devices Market in China (2021-2030)
• Table 20: Neurostimulation Devices Market in Japan (2021-2030)
• Table 21: Neurostimulation Devices Market in India (2021-2030)
• Table 22: Neurostimulation Devices Market in Australia (2021-2030)
• Table 23: Neurostimulation Devices Market in South Korea (2021-2030)
• Table 24: Neurostimulation Devices Market in Rest of Asia-Pacific (2021-2030)
• Table 25: Neurostimulation Devices Market in the Rest of the World (2021-2030)
• Table 26: Neurostimulation Devices Market in the Middle East (2021-2030)
• Table 27: Neurostimulation Devices Market in Africa (2021-2030)
• Table 28: Neurostimulation Devices Market in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: Neurostimulation Devices Market in Global (2021-2030)
• Figure 3: Neurostimulation Devices Market in Global by Device Type (2021-2030)
• Figure 4: Neurostimulation Devices Market in Global by Application (2021-2030)
• Figure 5: Neurostimulation Devices Market in Global by Type (2021-2030)
• Figure 6: Neurostimulation Devices Market in Global by Geography (2021-2030)
• Figure 7: Neurostimulation Devices Market in North America (2021-2030)
• Figure 8: Neurostimulation Devices Market in the US (2021-2030)
• Figure 9: Neurostimulation Devices Market in Canada (2021-2030)
• Figure 10: Neurostimulation Devices Market in Mexico (2021-2030)
• Figure 11: Neurostimulation Devices Market in Europe (2021-2030)
• Figure 12: Neurostimulation Devices Market in France (2021-2030)
• Figure 13: Neurostimulation Devices Market in Germany (2021-2030)
• Figure 14: Neurostimulation Devices Market in the United Kingdom (2021-2030)
• Figure 15: Neurostimulation Devices Market in Italy (2021-2030)
• Figure 16: Neurostimulation Devices Market in Spain (2021-2030)
• Figure 17: Neurostimulation Devices Market in Rest of Europe (2021-2030)
• Figure 18: Neurostimulation Devices Market in Asia-Pacific (2021-2030)
• Figure 19: Neurostimulation Devices Market in China (2021-2030)
• Figure 20: Neurostimulation Devices Market in Japan (2021-2030)
• Figure 21: Neurostimulation Devices Market in India (2021-2030)
• Figure 22: Neurostimulation Devices Market in Australia (2021-2030)
• Figure 23: Neurostimulation Devices Market in South Korea (2021-2030)
• Figure 24: Neurostimulation Devices Market in Rest of Asia-Pacific (2021-2030)
• Figure 25: Neurostimulation Devices Market in the Rest of the World (2021-2030)
• Figure 26: Neurostimulation Devices Market in the Middle East (2021-2030)
• Figure 27: Neurostimulation Devices Market in Africa (2021-2030)
• Figure 28: Neurostimulation Devices Market in South America (2021-2030)
• Figure 29: Market Drivers
• Figure 30: Market Barriers
• Figure 31: Market Opportunities
• Figure 32: PORTER'S Five Force Analysis

Neurostimulation Devices Market By Device Type (Spinal Cord Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, Vagus Nerve Stimulators, and Others), Application (Pain Management, Bowel and Bladder Control, Parkinson's Disease, Epilepsy, and Others), Type (Invasive, and Non-Invasive), End-User (Hospitals, Ambulatory Surgical Centres, and Others), and Geography is expected to grow at a steady CAGR Forecast till 2030 owing to increasing incidence of chronic diseases and escalating product demand as add-on therapy

The global neurostimulation devices market was valued at USD 5.82 billion in 2023, growing at a CAGR of 11.77% during the forecast period from 2024 to 2030, to reach USD 11.34 billion by 2030. The demand for neurostimulation devices is primarily motivated by the increasing incidence of chronic neurological diseases, such as migraine and epilepsy, escalating product demand as add-on therapy, the prevalence of lifestyle diseases such as depression and chronic pain, the adoption of technologically advanced products, and rising geriatric population among others during the forecast period.

Neurostimulation Devices Market Dynamics:

Neurological disorders, consisting of stroke, brain and other nervous system cancers, traumatic brain injury, spinal cord injury, Alzheimer's disease and other dementias, Parkinson's disease, epilepsy, and migraine, among others, are the leading cause of disability. The absolute number of people affected by, or remaining disabled from neurological disorders over the past 25 years has been increasing globally, as per the Global Burden of Disease Study 2019. These disorders are increasingly recognized as one of the most prevalent disorders with a high burden to the patients, their families, and society. As per the data published by the Epilepsy Centre in 2020, around 50 million patients are living with epilepsy worldwide, and around 2.4 million new cases are diagnosed annually. Moreover, the majority of epileptic cases are idiopathic, with no identifiable cause.

Parkinson's disease (PD) affects 1-2 per 1000 of the population at any time, as per the Global Burden of Disease Study 2019. PD prevalence is increasing with age and PD affects 1% of the population above 60 years.

According to World Health Organisation (2023) data, around 50 million people globally have dementia, and there are nearly 10 million new cases every year. Around 60-70% of these cases are of Alzheimer's. Urgent measures to reduce this burden are therefore needed. The increasing number of neurological cases around the globe is expected to boost the demand for neurostimulation devices in the market.

Moreover, companies are increasing their research and development to develop products with better efficacy and easy. High product efficacy demonstrated in treating neurological conditions along with the availability of limited treatment options for the disease is expected to impel market growth during the forecast period. Rising cases of depression are also likely to contribute to market development as neurostimulation devices provide easy treatment by activating or inhibiting electrical brain signals.

An aging population contributed to the increase in numbers. As per the recent survey, Global Population Aging 2020 Report (United Nations, 2020), the aging population tends to grow at an alarming pace. In 2020, there were around 727 million individuals in the world aged 65 years or older. By 2050, the figure of such patients is expected to double and reach 1.5 billion by 2050. Thus, all these factors are projected to drive the growth of the neurostimulation devices market.

Certain factors such as the surgical complications during implantation of the devices, the high cost of the products, less awareness in low-economic countries, high chances of infections, and product getting recalled, pose as a minor hurdle for the neurostimulation devices growth in the market.

Neurostimulation Devices Segment Analysis:

By Device Type (Spinal Cord Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, Vagus Nerve Stimulators, and Others), Application (Pain Management, Bowel and Bladder Control, Parkinson's Disease, Epilepsy, and Others), Type (Invasive, and Non-Invasive), End-User (Hospitals, Ambulatory Surgical Centres, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the devices type segment, spinal cord stimulators are expected to hold the largest share in the market as neurostimulation devices.

The increased use of spinal cord stimulators, also known as dorsal column stimulation, for treating neuropathic pain and spinal injuries is contributing to this segment's growth. The therapy is more intrusive than percutaneous injection therapy but less invasive than back surgery and uses pulsed electrical energy near the spinal cord to manage pain.

In addition, an upsurge in minimally invasive procedures and an increase in healthcare spending further drive the market growth for spinal cord stimulators across the globe.

The spinal cord stimulator segment is expected to grow at a significant CAGR, owing to the usage of DBS in various diseases such as Parkinson's disease, obsessive-compulsive disorders, idiopathic dystonia, & essential tremor and growth in several product approvals.

In the application segment, the pain management segment is the highest contributor to the neurostimulation devices market, due to the increase in usage of neurostimulation devices for treating chronic and acute pain. Some of the diseases encompassed under this segment include chronic pain, disk surgery pain, and leg pain.

Additionally, assistance from government bodies, approval of more devices in the segment, increased awareness, and increased healthcare spending, is expected to enhance the market potential in several countries. Hence, all the above-mentioned factors are expected to drive segment growth in neurostimulation devices.

North America is expected to dominate the overall Neurostimulation Devices Market:

North America is expected to dominate the overall neurostimulation devices market during the forecast period. This domination is due to the growing number of patients suffering from various neurological conditions, rising product launches and approvals, the presence of key market players in the region, and others that will increase the demand for neurostimulation devices during the forecast period.

For instance, as per the data provided by the Alzheimer Association (2023), more than 6 million Americans are living with Alzheimer's. By 2050, this number is projected to rise to nearly 13 million.

As per the Parkinson's Foundation 2022 study, every year in the United States about 90,000 people are diagnosed with Parkinson's disease. The treatment through neurostimulation devices is expected to lower the burden and improve living conditions.

Moreover, an increase in product approval by FDA is also a driving factor for neurostimulation devices in the region. For instance, in June 2020, Medtronic received Food and Drug Administration (FDA) approval for the Percept(TM) PC Deep Brain Stimulation (DBS) system.

Therefore, the interplay of the aforementioned factors above would provide a conducive growth environment for the North American region in the neurostimulation devices market.

Neurostimulation Devices Key Players:

Some of the key market players operating in the Neurostimulation Devices Market include Medtronic PLC, Cyberonics, Boston Scientific Corporation, Abbott Laboratories, Aleva Neurotherapeutic, ElectroCore Inc., EndoStim Inc., Nevro Corporation, and others.

Recent Developmental Activities in Neurostimulation Devices Market:

In August 2022, Merck announced a collaboration in its new Bioelectronics innovation field with neuroloop GmbH, a B. Braun subsidiary, to develop a neurostimulator device that can complement the existing drug therapies of patients with chronic inflammatory diseases.

In July 2022, Unity HA received Breakthrough Device Designation by FDA for the Pulsante® SPG Microstimulator System for the treatment of acute pain associated with chronic cluster headaches.

In July 2022, Nevro Corp. received FDA approval for its Senza® System for the treatment of chronic pain associated with painful diabetic neuropathy (PDN).

Key Takes Away from the Neurostimulation Devices Market Report Study

Market size analysis for current market size (2023), and market forecast for 5 years (2024-2030)

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the global neurostimulation devices market.

Various opportunities available for the other competitor in the neurostimulation devices market space.

What are the top-performing segments in 2023? How these segments will perform in 2030?

Which are the top-performing regions and countries in the current market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for market growth in the coming future?

Target Audience who can be benefited from this Neurostimulation Devices Market Report Study

Neurostimulation Devices providers

Research organizations and consulting companies

Cardiopulmonary Bypass Equipment-related organization, association, forum, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders

Various End-Users who want to know more about the neurostimulation devices market and the latest technological developments in the neurostimulation devices market.

Frequently Asked Questions for Neurostimulation Devices Market:

1. What are Neurostimulation Devices?

Neurostimulation devices are implantable or non-implantable medical devices that provide electrical stimulation to specific parts of the patient's brain, spinal cord, or peripheral nervous system to treat numerous conditions, including chronic pain, movement disorders, epilepsy, and Parkinson's disease.

2. What is the market for global neurostimulation devices?

The global neurostimulation devices market was valued at USD 5.82 billion in 2023, growing at a CAGR of 11.77% during the forecast period from 2024 to 2030, to reach USD 11.34 billion by 2030.

3. What are the drivers for the neurostimulation devices market?

The major drivers driving the demand for neurostimulation devices are the growing incidence of chronic diseases, such as migraine and epilepsy, increasing product demand as add-on therapy, rise in prevalence of lifestyle diseases such as depression and chronic pain, adoption of technologically advanced products, and rising geriatric population.

4. What are the key players operating in the global neurostimulation devices market?

Some of the key market players operating in the neurostimulation devices market include Medtronic PLC, Cyberonics, Boston Scientific Corporation, Abbott Laboratories, Aleva neurotherapeutics SA, ElectroCore Inc., EndoStim Inc., Nevro Corporation, and others.

5. Which region has the highest share in the neurostimulation devices market?

North America is expected to dominate the overall neurostimulation devices market during the forecast period, 2024 to 2030. This domination is due to the growing number of patients suffering from various neurological conditions, the increase in the prevalence of neurological disorders and lifestyle-related disorders, and the demand for advanced technologies in neurostimulation devices

Table of Contents

1. Neurostimulation Devices Market Report Introduction

2. Neurostimulation Devices Market Executive Summary

• 2.1 Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment

3. Regulatory Analysis

• 3.1. The United States
• 3.2. Europe
• 3.3. Japan
• 3.4. China

4. Neurostimulation Devices Market Key Factors Analysis

• 4.1. Neurostimulation Devices Market Drivers
  • 4.1.1. Increasing incidence of chronic diseases, such as migraine and epilepsy
  • 4.1.2. Escalating product demand as add-on therapy
  • 4.1.3. Prevalence of lifestyle diseases such as depression and chronic pain
  • 4.1.4. Adoption of technologically advanced products
  • 4.1.5. Rising geriatric population
• 4.2. Neurostimulation Devices Market Restraints and Challenges
  • 4.2.1. High cost of products and risk of infection during the surgery
  • 4.2.2. Strict regulations by regulatory bodies
• 4.3. Neurostimulation Devices Market Opportunities
  • 4.3.1. Growing demand for neurostimulation device due to increasing cases of neurological conditions
  • 4.3.2. Awareness towards better lifestyle modifications

5. Neurostimulation Devices Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. Neurostimulation Devices Market Layout

• 6.1. By Device Type
  • 6.1.1. Spinal Cord Stimulators
  • 6.1.2. Deep Brain Stimulators
  • 6.1.3. Sacral Nerve Stimulators
  • 6.1.4. Vagus Nerve Stimulators
  • 6.1.5. Others
• 6.2. By Application
  • 6.2.1. Pain Management
  • 6.2.2. Hearing Loss
  • 6.2.3. Urinary Incontinence
  • 6.2.4. Parkinson's Disease
  • 6.2.5. Epilepsy
  • 6.2.6. Others
• 6.3. By Type
  • 6.3.1. Invasive
  • 6.3.2. Non-Invasive
• 6.4. By End-User
  • 6.4.1. Hospitals
  • 6.4.2. Speciality Clinics
• 6.5. By Geography
  • 6.5.1. North America Neurostimulation Devices Market Size in USD million (2021-2030)
    • 6.5.1.1. United States Neurostimulation Devices Market Size in USD million (2021-2030)
    • 6.5.1.2. Canada Neurostimulation Devices Market Size in USD million (2021-2030)
    • 6.5.1.3. Mexico Neurostimulation Devices Market Size in USD million (2021-2030)
  • 6.5.2. Europe Neurostimulation Devices Market Size in USD million (2021-2030)
    • 6.5.2.1. France Neurostimulation Devices Market Size in USD million (2021-2030)
    • 6.5.2.2. Germany Neurostimulation Devices Market Size in USD million (2021-2030)
    • 6.5.2.3. United Kingdom Neurostimulation Devices Market Size in USD million (2021-2030)
    • 6.5.2.4. Italy Neurostimulation Devices Market Size in USD million (2021-2030)
    • 6.5.2.5. Spain Neurostimulation Devices Market Size in USD million (2021-2030)
    • 6.5.2.6. Rest of Europe Neurostimulation Devices Market Size in USD million (2021-2030)
  • 6.5.3. Asia-Pacific Neurostimulation Devices Market Size in USD million (2021-2030)
    • 6.5.3.1. China Neurostimulation Devices Market Size in USD million (2021-2030)
    • 6.5.3.2. Japan Neurostimulation Devices Market Size in USD million (2021-2030)
    • 6.5.3.3. India Neurostimulation Devices Market Size in USD million (2021-2030)
    • 6.5.3.4. Australia Neurostimulation Devices Market Size in USD million (2021-2030)
    • 6.5.3.5. South Korea Neurostimulation Devices Market Size in USD million (2021-2030)
    • 6.5.3.6. Rest of Asia-Pacific Neurostimulation Devices Market Size in USD million (2021-2030)
  • 6.5.4. Rest of the World (RoW) Neurostimulation Devices Market Size in USD million (2021-2030)
    • 6.5.4.1. Middle East Neurostimulation Devices Market Size in USD million (2021-2030)
    • 6.5.4.2. Africa Neurostimulation Devices Market Size in USD million (2021-2030)
    • 6.5.4.3. South America Neurostimulation Devices Market Size in USD million (2021-2030)

7.Neurostimulation Devices Company and Product Profiles

• 7.1. Medtronic Plc
  • 7.1.1. Company Overview
  • 7.1.2. Company Snapshot
  • 7.1.3. Financial Overview
  • 7.1.4. Product Listing
  • 7.1.5. Entropy
• 7.2. Cyberonics
  • 7.2.1. Company Overview
  • 7.2.2. Company Snapshot
  • 7.2.3. Financial Overview
  • 7.2.4. Product Listing
  • 7.2.5. Entropy
• 7.3. Boston Scientific Corporation
  • 7.3.1. Company Overview
  • 7.3.2. Company Snapshot
  • 7.3.3. Financial Overview
  • 7.3.4. Product Listing
  • 7.3.5. Entropy
• 7.4. Abbott Laboratories
  • 7.4.1. Company Overview
  • 7.4.2. Company Snapshot
  • 7.4.3. Financial Overview
  • 7.4.4. Product Listing
  • 7.4.5. Entropy
• 7.5. Aleva neurotherapeutics SA
  • 7.5.1. Company Overview
  • 7.5.2. Company Snapshot
  • 7.5.3. Financial Overview
  • 7.5.4. Product Listing
  • 7.5.5. Entropy
• 7.6. ElectroCore Inc.
  • 7.6.1. Company Overview
  • 7.6.2. Company Snapshot
  • 7.6.3. Financial Overview
  • 7.6.4. Product Listing
  • 7.6.5. Entropy
• 7.7. EndoStim Inc.
  • 7.7.1. Company Overview
  • 7.7.2. Company Snapshot
  • 7.7.3. Financial Overview
  • 7.7.4. Product Listing
  • 7.7.5. Entropy
• 7.8. Nevro Corporation
  • 7.8.1. Company Overview
  • 7.8.2. Company Snapshot
  • 7.8.3. Financial Overview
  • 7.8.4. Product Listing
  • 7.8.5. Entropy
• 7.9. LivaNova PLC
  • 7.9.1. Company Overview
  • 7.9.2. Company Snapshot
  • 7.9.3. Financial Overview
  • 7.9.4. Product Listing
  • 7.9.5. Entropy
• 7.10. NDI Medical, LLC
  • 7.10.1. Company Overview
  • 7.10.2. Company Snapshot
  • 7.10.3. Financial Overview
  • 7.10.4. Product Listing
  • 7.10.5. Entropy
• 7.11. Neuronetics
  • 7.11.1. Company Overview
  • 7.11.2. Company Snapshot
  • 7.11.3. Financial Overview
  • 7.11.4. Product Listing
  • 7.11.5. Entropy
• 7.12. NeuroSigma Inc.
  • 7.12.1. Company Overview
  • 7.12.2. Company Snapshot
  • 7.12.3. Financial Overview
  • 7.12.4. Product Listing
  • 7.12.5. Entropy
• 7.13. CODMAN & SHURTLEFF'S
  • 7.13.1. Company Overview
  • 7.13.2. Company Snapshot
  • 7.13.3. Financial Overview
  • 7.13.4. Product Listing
  • 7.13.5. Entropy
• 7.14. INTRAPACE
  • 7.14.1. Company Overview
  • 7.14.2. Company Snapshot
  • 7.14.3. Financial Overview
  • 7.14.4. Product Listing
  • 7.14.5. Entropy
• 7.15. B. Braun SE Melsungen
  • 7.15.1. Company Overview
  • 7.15.2. Company Snapshot
  • 7.15.3. Financial Overview
  • 7.15.4. Product Listing
  • 7.15.5. Entropy

8. KOL Views

9. Project Approach

10. DelveInsight Capabilities

11. About DelveInsight

12. Disclaimer & Contact Us